Bayer for ProfessionalsYour Resource Portal

PP-PF-OTH-GB-0056 | February 2024

Explore BayerPRO Podcasts

Oncology

Oncology Podcast

Current treatment landscape and the future for treating mCRC

Stivarga® (regorafenib)

Stivarga Prescribing Information

PP-STI-GB-0201, February 2024

Episode 3

The Practicalities of Treatment — Xofigo®▼ (radium-223 dichloride)

Xofigo Prescribing Information

PP-XOF-GB-0464, February 2024

Episode 1

Why treat with Xofigo®▼ (radium-223 dichloride)?

Xofigo Prescribing Information

PP-XOF-GB-0462, February 2024

Episode 2

Optimising patient identification and referral — Xofigo®▼ (radium-223 dichloride)

Xofigo Prescribing Information

PP-XOF-GB-0463, February 2024

Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.

Further information is available on the "contact" tab at www.bayer.co.uk.